Related Experiment Video

Updated: Jul 2, 2026

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

Agonist-selective, receptor-specific interaction of human P2Y receptors with beta-arrestin-1 and -2

Carsten Hoffmann1, Nicole Ziegler, Susanne Reiner

  • 1Institute for Pharmacology and Toxicology, Versbacher Strasse 9, D-97078 Wuerzburg, Germany. c.Hoffmann@toxi.uni-wuerzburg.de

The Journal of Biological Chemistry
|August 16, 2008
PubMed

Insights

G-protein-coupled receptor (GPCR) interactions with beta-arrestins are key for receptor regulation. This study reveals distinct P2Y receptor and beta-arrestin interactions, with P2Y(2) showing agonist-dependent signaling via different beta-arrestin recruitment patterns.

Area of Science:

  • Pharmacology
  • Cell Biology
  • Molecular Biology

Background:

  • G-protein-coupled receptors (GPCRs) mediate cellular responses through interactions with signaling proteins.
  • Beta-arrestins play crucial roles in GPCR desensitization, internalization, and signal transduction.
  • Understanding P2Y receptor interactions with beta-arrestins is vital for elucidating purinergic signaling pathways.

Purpose of the Study:

  • To investigate the internalization and beta-arrestin interaction patterns of human P2Y receptors (1, 2, 4, 6, 11, and 12).
  • To determine the influence of different agonists on P2Y receptor and beta-arrestin complex formation.
  • To explore the functional consequences of ligand-specific beta-arrestin recruitment on downstream signaling, specifically ERK phosphorylation.

Main Methods:

  • Confocal microscopy and fluorescence resonance energy transfer (FRET) were employed to visualize receptor internalization and protein-protein interactions.
  • HEK-293 cells were co-transfected with individual P2Y receptors and fluorescently tagged beta-arrestin-1 or beta-arrestin-2.
  • Cells were stimulated with specific agonists (ADP, UTP, ATP) to induce receptor activation and subsequent beta-arrestin recruitment.

Main Results:

  • P2Y receptor interactions with beta-arrestins were found to be receptor- and agonist-specific.
  • P2Y(2) receptor exhibited distinct beta-arrestin recruitment patterns depending on whether stimulated with ATP or UTP, classifying it as Class A or Class B respectively.
  • Ligand-specific beta-arrestin recruitment by P2Y(2) receptors led to differential ERK phosphorylation, indicating distinct active receptor states.

Conclusions:

  • Human P2Y receptors display diverse interaction profiles with beta-arrestin-1 and beta-arrestin-2.
  • The P2Y(2) receptor demonstrates functional selectivity, with different agonists inducing distinct signaling pathways through differential beta-arrestin engagement.
  • Agonist-driven conformational changes in P2Y receptors dictate their interaction with beta-arrestins, leading to varied downstream cellular responses.

More Related Videos

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay09:03

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Published on: March 10, 2020

Related Concept Videos

Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...